JP2022501336A5 - - Google Patents
Info
- Publication number
- JP2022501336A5 JP2022501336A5 JP2021514344A JP2021514344A JP2022501336A5 JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5 JP 2021514344 A JP2021514344 A JP 2021514344A JP 2021514344 A JP2021514344 A JP 2021514344A JP 2022501336 A5 JP2022501336 A5 JP 2022501336A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- optionally
- phytosterols
- seq
- peg
- Prior art date
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862731335P | 2018-09-14 | 2018-09-14 | |
| US62/731,335 | 2018-09-14 | ||
| US201862770024P | 2018-11-20 | 2018-11-20 | |
| US62/770,024 | 2018-11-20 | ||
| US201962881322P | 2019-07-31 | 2019-07-31 | |
| US62/881,322 | 2019-07-31 | ||
| PCT/US2019/051072 WO2020056304A1 (en) | 2018-09-14 | 2019-09-13 | Methods and compositions for treating cancer using mrna therapeutics |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2022501336A JP2022501336A (ja) | 2022-01-06 |
| JP2022501336A5 true JP2022501336A5 (https=) | 2022-09-20 |
| JPWO2020056304A5 JPWO2020056304A5 (https=) | 2022-09-20 |
| JP7556848B2 JP7556848B2 (ja) | 2024-09-26 |
Family
ID=68104746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021514344A Active JP7556848B2 (ja) | 2018-09-14 | 2019-09-13 | ｍＲＮＡ治療薬を使用したがんを治療するための方法及び組成物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230081530A1 (https=) |
| EP (1) | EP3849589A1 (https=) |
| JP (1) | JP7556848B2 (https=) |
| CN (1) | CN113015540A (https=) |
| AU (1) | AU2019338535A1 (https=) |
| CA (1) | CA3112781A1 (https=) |
| WO (1) | WO2020056304A1 (https=) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| US20220280639A1 (en) * | 2019-07-31 | 2022-09-08 | Modernatx, Inc. | Compositions and methods for delivery of rna interference agents to immune cells |
| JP2023526059A (ja) * | 2020-05-14 | 2023-06-20 | モダーナティエックス・インコーポレイテッド | ｍＲＮＡ治療薬及びエフェクター分子を含むＬＮＰ組成物 |
| US12188060B2 (en) | 2020-05-15 | 2025-01-07 | Crispr Therapeutics Ag | Messenger RNA encoding Cas9 for use in genome-editing systems |
| WO2022010764A1 (en) * | 2020-07-06 | 2022-01-13 | Vivtex Corporation | Mucopenetrating formulations |
| IL303195A (en) | 2020-11-25 | 2023-07-01 | Akagera Medicines Inc | Lipid nanoparticles for delivery of nucleic acids and related methods of use |
| WO2022120560A1 (zh) * | 2020-12-08 | 2022-06-16 | 深圳市瑞吉生物科技有限公司 | 一种mRNA剂型的免疫抑制剂及其在制备肿瘤治疗药物中的应用 |
| US20240200106A1 (en) * | 2021-04-17 | 2024-06-20 | Intellia Thrapeutics, Inc. | Lipid nanoparticles compositions |
| CN116406426A (zh) * | 2021-04-29 | 2023-07-07 | 苏州沙砾生物科技有限公司 | 一种修饰的肿瘤浸润淋巴细胞及其用途 |
| US20220364078A1 (en) | 2021-05-14 | 2022-11-17 | Crispr Therapeutics Ag | Mrna large scale synthesis and purification |
| US12251471B2 (en) * | 2021-07-26 | 2025-03-18 | Oregon State University | Inhalable therapeutics |
| CN114457054A (zh) * | 2022-02-24 | 2022-05-10 | 中国科学技术大学 | 一种cGAS mRNA的制备及作为免疫激活剂的应用 |
| US20250312430A1 (en) * | 2022-03-30 | 2025-10-09 | The Johns Hopkins University | Compositions of lipid nanoparticles for plasmid dna delivery to the liver and methods for preparing the same |
| EP4531819A2 (en) | 2022-05-25 | 2025-04-09 | Akagera Medicines, Inc. | Lipid nanoparticles for delivery of nucleic acids and methods of use thereof |
| CN119486749A (zh) * | 2022-06-22 | 2025-02-18 | 武汉厚先生物医药有限公司 | Il-12和ox40l组合物在肿瘤免疫治疗中的应用 |
| WO2024015955A2 (en) * | 2022-07-15 | 2024-01-18 | President And Fellows Of Harvard College | Mucispirillum compositions and cancer treatment methods thereof |
| US20250387486A1 (en) * | 2022-08-09 | 2025-12-25 | Stemirna Therapeutics Co., Ltd. | Lipid composition |
| CN115869332A (zh) * | 2022-10-27 | 2023-03-31 | 北京新合睿恩生物医疗科技有限公司 | 递送至体内后在肝脏少表达的mRNA药物及其制备方法 |
| EP4649087A2 (en) | 2023-01-11 | 2025-11-19 | Engage Biologics Inc. | Non-viral expression systems and methods of use thereof |
| EP4470559A1 (en) * | 2023-06-02 | 2024-12-04 | Imgen-T-Srl | Combination containing an mrna vaccine and an immune modulating mrna for improved immunogenicity and efficacy |
| WO2025098508A1 (zh) * | 2023-11-10 | 2025-05-15 | 贝达药业股份有限公司 | 标记性多肽、治疗剂及其应用 |
| CN119662655A (zh) * | 2023-12-04 | 2025-03-21 | 武汉厚先生物医药有限公司 | Rna分子及其组合物在肿瘤免疫治疗中的应用 |
| WO2026078565A1 (en) | 2024-10-10 | 2026-04-16 | Crispr Therapeutics Ag | Messenger rna encoding cas9 for use in genome-editing systems |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2390331B1 (en) | 2001-09-28 | 2018-04-25 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | MicroRNA molecules |
| US20050222064A1 (en) | 2002-02-20 | 2005-10-06 | Sirna Therapeutics, Inc. | Polycationic compositions for cellular delivery of polynucleotides |
| US7683036B2 (en) | 2003-07-31 | 2010-03-23 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding RNAs |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| NZ582330A (en) * | 2007-06-27 | 2012-05-25 | Marinepolymer Tech Inc | COMPLEXES OF IL-15 AND IL-15Ra (RECEPTOR ALPHA) AND USES THEREOF |
| DK2205618T3 (en) | 2007-09-26 | 2017-02-20 | Intrexon Corp | SYNTHETIC 5 'NON-TRANSLATED REGIONS, EXPRESSION VECTORS AND PROCEDURES FOR INCREASING TRANSGENIC EXPRESSION |
| MX342785B (es) | 2009-06-10 | 2016-10-12 | Alnylam Pharmaceuticals Inc | Formulacion mejorada de lipido. |
| RU2013120302A (ru) | 2010-10-01 | 2014-11-20 | Модерна Терапьютикс, Инк. | Сконструированные нуклеиновые кислоты и способы их применения |
| CA2824526C (en) | 2011-01-11 | 2020-07-07 | Alnylam Pharmaceuticals, Inc. | Pegylated lipids and their use for drug delivery |
| WO2013103659A1 (en) | 2012-01-04 | 2013-07-11 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Stabilizing rna by incorporating chain-terminating nucleosides at the 3'-terminus |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| WO2014081507A1 (en) | 2012-11-26 | 2014-05-30 | Moderna Therapeutics, Inc. | Terminally modified rna |
| US20140200261A1 (en) | 2013-01-17 | 2014-07-17 | Moderna Therapeutics, Inc. | Signal-sensor polynucleotides for the alteration of cellular phenotypes |
| US20160022840A1 (en) | 2013-03-09 | 2016-01-28 | Moderna Therapeutics, Inc. | Heterologous untranslated regions for mrna |
| EP2968391A1 (en) | 2013-03-13 | 2016-01-20 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10821175B2 (en) | 2014-02-25 | 2020-11-03 | Merck Sharp & Dohme Corp. | Lipid nanoparticle vaccine adjuvants and antigen delivery systems |
| SMT202200502T1 (it) | 2014-06-25 | 2023-01-13 | Acuitas Therapeutics Inc | Nuovi lipidi e formulazioni di nanoparticelle lipidiche per l'erogazione di acidi nucleici |
| SG11201702295UA (en) | 2014-09-22 | 2017-04-27 | Intrexon Corp | Improved therapeutic control of heterodimeric and single chain forms of interleukin-12 |
| RU2749113C2 (ru) * | 2015-04-22 | 2021-06-04 | Куревак Аг | Содержащая рнк композиция для лечения опухолевых заболеваний |
| IL307179A (en) | 2015-10-28 | 2023-11-01 | Acuitas Therapeutics Inc | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids |
| HRP20220652T1 (hr) | 2015-12-10 | 2022-06-24 | Modernatx, Inc. | Pripravci i postupci unosa terapijskih sredstava |
| RS63135B1 (sr) * | 2015-12-23 | 2022-05-31 | Modernatx Inc | Postupci upotrebe polinukleotida koji kodiraju ox40 ligand |
| EP3458474B1 (en) * | 2016-05-18 | 2022-07-06 | ModernaTX, Inc. | Combinations of mrnas encoding immune modulating polypeptides and uses thereof |
| WO2017201352A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Mrna combination therapy for the treatment of cancer |
| KR102469450B1 (ko) * | 2016-05-18 | 2022-11-22 | 모더나티엑스, 인크. | 인터류킨-12 (il12)를 코딩하는 폴리뉴클레오티드 및 그의 용도 |
| JP2019532648A (ja) | 2016-10-07 | 2019-11-14 | ボード オブ リージェンツ ザ ユニヴァーシティ オブ テキサス システム | がんの治療のための膜係留ｉｌ−１２を発現しているｔ細胞 |
| JP7285220B2 (ja) | 2017-05-18 | 2023-06-01 | モデルナティエックス インコーポレイテッド | 連結したインターロイキン－１２（ｉｌ１２）ポリペプチドをコードするポリヌクレオチドを含む脂質ナノ粒子 |
| JP2021512090A (ja) | 2018-01-30 | 2021-05-13 | モデルナティーエックス， インコーポレイテッド | 免疫細胞に薬剤を送達するための組成物及び方法 |
-
2019
- 2019-09-13 US US17/275,832 patent/US20230081530A1/en not_active Abandoned
- 2019-09-13 WO PCT/US2019/051072 patent/WO2020056304A1/en not_active Ceased
- 2019-09-13 CN CN201980074987.2A patent/CN113015540A/zh active Pending
- 2019-09-13 JP JP2021514344A patent/JP7556848B2/ja active Active
- 2019-09-13 EP EP19780053.5A patent/EP3849589A1/en active Pending
- 2019-09-13 CA CA3112781A patent/CA3112781A1/en active Pending
- 2019-09-13 AU AU2019338535A patent/AU2019338535A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501336A5 (https=) | ||
| JPWO2020056304A5 (https=) | ||
| Liu et al. | Advances in immunotherapy for triple-negative breast cancer | |
| US8367628B2 (en) | Amphoteric liposome formulation | |
| Xu et al. | Endogenous sialic acid-engineered micelles: a multifunctional platform for on-demand methotrexate delivery and bone repair of rheumatoid arthritis | |
| JP2020520640A5 (https=) | ||
| CN104903450A (zh) | 寡核苷酸癌症疗法的给药和施用 | |
| JP5623016B2 (ja) | 癌治療法およびそれに用いる医薬組成物 | |
| JP2020111589A (ja) | リポソーム製剤 | |
| CN116133640A (zh) | 脂质纳米颗粒 | |
| Fan et al. | Lipid-based nanoparticles for cancer immunotherapy | |
| CN104884637A (zh) | 利用生物标志物通过bcl2表达的调节治疗癌症的方法 | |
| CN108310378A (zh) | 一类新型免疫联体抗肿瘤创新药物的制备及其应用 | |
| JP2022525223A (ja) | ｓＥｐｈＢ４－ＨＳＡ融合タンパク質を用いたがんの治療 | |
| TW202114647A (zh) | 用於治療具有高間質壓力的腫瘤受試者的癌症的小分子抑制劑 | |
| KR20240158980A (ko) | 유기 화합물 | |
| WO2009051712A1 (en) | Dnai amphoteric liposome formulation | |
| CN108883068A (zh) | 使用紫杉烷的阳离子微脂体制剂、紫杉烷的非微脂体制剂和其他活性药剂合并治疗乳癌的方法 | |
| WO2024137776A1 (en) | Combination therapy for lung cancer | |
| WO2023161378A1 (en) | Polymer-lipid hybrid nanoparticles comprising a lipid and a block copolymer as well as methods of making and uses thereof | |
| WO2007065017A2 (en) | Oligonucleotide cationic liposomal delivery system | |
| WO2020160409A1 (en) | Methods of treating cancer using a combination of tumor membrane vesicles and metformin | |
| WO2022097634A1 (ja) | 血管新生依存性疾患治療に使用される医薬用組成物 | |
| CN116621966B (zh) | 治疗性核酸分子、混合物、药物及在治疗实体瘤中的应用 | |
| WO2023121960A2 (en) | Compositions and methods for delivery and production of antibodies using an rna-containing nanoparticle platform |